Developing High-quality Data Analytics
There are 76,000 registered molecular tests, half of which are registered in the United States. For health payers, the process for reviewing these tests is mostly manual which makes it burdensome, costly and inefficient. This inefficiency leads to wasteful spending.
For the test makers (biotech companies), test differentiation is a challenge. The true value proposition of a test is often overlooked due to the inefficiencies around the burdensome health payer review process, which often yields discordant findings.
Our solution decreases the health payers' test review time by about 95%, and provides biotech companies with an unbiased platform for test review and enhanced product positioning.
DrPIE will lead the healthcare industry in choosing effective diagnostics that improve health outcomes through improved decision-making solutions for determining health payer coverage.